Brief: Izervay® (Avacincaptad Pegol Intravitreal Solution) Demonstrated Increased Probability Of Maintaining Driving Eligibility In Geographic Atrophy Patients
12/05/2026 14:41
May 12 (Reuters) - Astellas Pharma Inc 4503.T: IZERVAY® (AVACINCAPTAD PEGOL INTRAVITREAL SOLUTION) DEMONSTRATED INCREASED PROBABILITY OF MAINTAINING DRIVING ELIGIBILITY IN GEOGRAPHIC ATROPHY PATIENTS ASTELLAS PHARMA INC - AT 24 MONTHS, IZERVAY SHOWS 41% RELATIVE RISK REDUCTION VERSUS SHAM FOR LOSS OF DRIVING ELIGIBILITY ASTELLAS PHARMA INC - GATHER2 DATA SHOW IZERVAY WELL-TOLERATED WITH NO NEW SAFETY SIGNALS Source text: ID:nPndMLj6a Further company coverage: 4503.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Astellas Pharma
See all newsBrief: Immuneering To Collaborate With Astellas On Clinical Studies Of Investigational CLDN18.2 Programs In Combination With Atebimetinib For Pancreatic Cancer Patients
Health Rounds: New blood test finds early risk for ovarian cancer
Health Rounds: New blood test finds early risk for ovarian cancer
Refile: Astellas employee imprisoned in China to be released in December, Japanese media report
Table: Astellas Pharma -6-MTH group results (IFRS)